Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

206 ta ish

Ish: Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

  1. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

    Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini +26

    Maqola20222 iqtibos
    ABI

  2. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig +25

    Maqola20222 iqtibos
    ABI

  3. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

    Tomáš Jelı́nek, Renata Bezděková, David Žihala +27

    Maqola20222 iqtibos
    ABI

  4. Chromosomal defects in multiple myeloma

    Sarah E. Clarke, Kathryn A. Fuller, Wendy N. Erber

    Sharh maqola20242 iqtibos
    ABI

  5. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu +34

    Maqola20242 iqtibos
    ABI

  6. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers

    Wei-Xin Xu, Qiang Qu, Hai-Hui Zhuang +5

    Maqola20242 iqtibos
    ABI

  7. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages

    Yan Cheng, Fumou Sun, Daisy Alapat +17

    Maqola20242 iqtibos
    ABI

  8. Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance

    Yuxin Liu, Anna L. Parks

    Sharh maqola20252 iqtibos
    ABI

  9. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

    Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur +43

    Maqola20252 iqtibos
    ABI

  10. Machine Learning-Based Predictive Model for Risk Stratification of Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance

    Amparo Santamaría, Marcos Alfaro, Cristina Antón Rodríguez +5

    Maqola20252 iqtibos
    ABI

  11. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

    Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe +3

    Maqola20222 iqtibos
    ABI

  12. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva +30

    Maqola20172 iqtibos
    ABI

  13. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

    David Murray, Noemí Puig, Sigurður Y. Kristinsson +10

    Maqola20212 iqtibos
    ABI

  14. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

    Mahdi Pakjoo, Seyed Esmaeil Ahmadi, Mohammad Zahedi +4

    Sharh maqola20242 iqtibos
    ABI

  15. Preliminary screening of biomarkers and drug candidates in a mouse model of β-thalassemia based on quasi-targeted metabolomics

    Xianfeng Guo, Xuchao Zhang, Min Li +3

    Maqola20242 iqtibos
    ABI

  16. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer

    Zibai Lyu, Siyue Niu, Ying Fang +3

    Sharh maqola20252 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI